First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults

• Main Authors: Jingrui Liu (Author), Xiaoxue Zhu (Author), Hong Zhang (Author), Haijing Wei (Author), Deming Yang (Author), Zhongnan Xu (Author), Dandan Huo (Author), Xiaojiao Li (Author), Yanhua Ding (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: As a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, TQ-F3083 represents a promising new drug for type 2 diabetes mellitus (T2DM). This phase I, first-in-human study evaluated the tolerability, pharmacokinetics, and pharmacodynamics of TQ-F3083 in healthy Chinese adults.Methods: Sixty he...